creatine and Atrophy
creatine has been researched along with Atrophy in 61 studies
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The X-linked creatine transporter deficiency (CRTD) caused by an SLC6A8 mutation represents the second most common cause of X-linked intellectual disability." | 7.85 | Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity. ( Dörr, HG; Heussinger, N; Mennecke, A; Saake, M; Trollmann, R, 2017) |
| " We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3." | 7.74 | Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008) |
| "The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months." | 7.72 | N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003) |
| "Gyrate atrophy of the choroid and retina is a disease characterized by progressive constriction of visual fields, a 10-fold to 20-fold elevation in plasma ornithine, and depressed activity of L-ornithine:2 oxoacid aminotransferase." | 7.66 | Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. ( Rapola, J; Simell, O; Sipilä, I; Vannas, A, 1981) |
| "Patients with gyrate atrophy of the choroid and retina have 10- to 20-fold increased ornithine concentrations in body fluids and significantly reduced activity of ornithine aminotransferase in lymphocytes and cultured fibroblasts." | 7.66 | Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. ( Arjomaa, P; Simell, O; Sipilä, I, 1980) |
| " Neuroimaging measures were central (ventricular) cerebral atrophy, lesion volume, and ratios of N-acetyl aspartate (NAA) to both creatine and choline." | 5.10 | Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. ( Christodoulou, C; Huang, W; Krupp, LB; Li, L; Li, X; Liang, Z; MacAllister, WS; Melville, P; Morgan, T; Peyster, R; Roche, P; Roque, C; Scherl, WF; Tudorica, LA, 2003) |
| "The X-linked creatine transporter deficiency (CRTD) caused by an SLC6A8 mutation represents the second most common cause of X-linked intellectual disability." | 3.85 | Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity. ( Dörr, HG; Heussinger, N; Mennecke, A; Saake, M; Trollmann, R, 2017) |
| " We observed mild cerebral and cerebellar atrophy and infarct at bilateral posterior putamen and insular cortex localization on conventional images and elevated choline/creatine ratios and abnormal peak at 3." | 3.74 | Neuroimaging findings in hyperargininemia. ( Akinci, A; Alkan, A; Firat, AK; Güngör, S; Tabel, Y, 2008) |
| "Mesial temporal lobe epilepsy (mTLE) is characterized by hippocampal atrophy, decreased N-acetyl-aspartate, and a low N-acetyl-aspartate/total creatine ratio, often attributed to neuron loss and gliosis." | 3.72 | N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus. ( Errante, LD; Kim, JH; Petroff, OA; Spencer, DD, 2003) |
| "The authors compared temporal profiles of N-acetylaspartate (NAA) and the NAA/total creatine ratio with neuronal and astrocytic densities and with tissue atrophy in the hippocampal CA1 sector of gerbils after 5-minute bilateral forebrain ischemia and subsequent reperfusion for up to 6 months." | 3.72 | N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy. ( Konaka, K; Li, JY; Matsumoto, M; Sakoda, S; Ueda, H; Yanagihara, T, 2003) |
| "To assess whether differences in cerebral atrophy and white matter lesions or in the presence of lactate and lipid signals can explain the observed differences in brain choline, creatine, and N-acetylaspartate levels between healthy elderly women and men." | 3.71 | Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites. ( Achten, E; Breteler, MM; De Groot, JC; De Leeuw, FE; Den Heijer, T; Heijboer, RJ; Hofman, A; Oudkerk, M; Sijens, PE, 2001) |
| " Thalamic and white matter metabolite concentrations (myo-inositol (mI), choline-containing compounds (Cho), total creatine (Cr) and N-acetylaspartate (NAA)) were estimated and corrected for atrophy (CSF) and gray and white matter contributions (GM, WM) by use of image-based voxel segmentation." | 3.71 | Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. ( Auer, DP; Bronisch, T; Grabner, A; Heidenreich, JO; Wetter, TC; Wilke, M, 2001) |
| "The N-acetylaspartate-to-creatine/phosphocreatine ratio was smaller in those patients with significant cerebral atrophy (1." | 3.69 | Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. ( Griffey, RH; Hart, BL; Haseler, LJ; Matwiyoff, NA; Sibbitt, RR; Sibbitt, WL, 1994) |
| "The aim of the study is to determine whether biochemical abnormalities, such as lipid, creatine and choline metabolites, are observed in the more distal muscles of polymyositis (PM) and dermatomyositis (DM) patients." | 3.69 | In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: a preliminary study. ( Chung, YL; Howlett, DC; Salisbury, JR; Scott, DL; Simmons, A; Smith, EC; Wassif, WS; Williams, SC, 1997) |
| " This study assessed urinary creatine excretion as a marker for testicular atrophy." | 3.68 | An investigation of urinary creatine excretion as a potential marker for testicular damage. ( le Net, JL; Nahas, K; Provost, JP; Tomaszewski, KE, 1993) |
| "Gyrate atrophy of the choroid and retina is a disease characterized by progressive constriction of visual fields, a 10-fold to 20-fold elevation in plasma ornithine, and depressed activity of L-ornithine:2 oxoacid aminotransferase." | 3.66 | Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. ( Rapola, J; Simell, O; Sipilä, I; Vannas, A, 1981) |
| "Patients with gyrate atrophy of the choroid and retina have 10- to 20-fold increased ornithine concentrations in body fluids and significantly reduced activity of ornithine aminotransferase in lymphocytes and cultured fibroblasts." | 3.66 | Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. ( Arjomaa, P; Simell, O; Sipilä, I, 1980) |
| "Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic event(s)." | 2.58 | Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder. ( Mountford, C; Quadrelli, S; Ramadan, S, 2018) |
| "Despite the high incidence of major depressive disorder (MDD) in females, the detailed neurobiology mechanism remains not fully understood." | 1.48 | Left fimbria atrophy is associated with hippocampal metabolism in female major depressive disorder patients. ( Cecilio Baro, C; Li, Y; Meng, Z; Tang, Y; Xu, J; Zhang, X, 2018) |
| "Hypertension is associated with cognitive decline in elderly persons." | 1.36 | Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes. ( Antequera, M; Antúnez, C; Campoy, G; Carrillo, A; Fuentes, LJ; García Santos, JM; García-Sevilla, J; Ortega, G; Torres del Río, S; Vidal, JB, 2010) |
| "Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency." | 1.35 | Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008) |
| "Chronic alcohol abuse results in morphological, metabolic, and functional brain damage which may, to some extent, be reversible with early effects upon abstinence." | 1.34 | Manifestations of early brain recovery associated with abstinence from alcoholism. ( Bartsch, AJ; Bendszus, M; Biller, A; De Stefano, N; Homola, G; Jenkinson, M; Smith, SM; Solymosi, L; Weijers, HG; Wiesbeck, GA, 2007) |
| "PEHO syndrome is a rare symptom complex of severe progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy." | 1.33 | Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome. ( Boltshauser, E; Huisman, TA; Klein, A; Straube, T; Werner, B, 2006) |
| "Eleven IDDM patients with no history of severe hypoglycemia (group A) were compared with 11 IDDM patients who had a history of five or more episodes of severe hypoglycemia (group B)." | 1.30 | Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. ( Best, JJ; Deary, IJ; Frier, BM; Perros, P; Sellar, RJ, 1997) |
| "Patients with AIDS had more signs of neurological dysfunction, poorer performance on a neuropsychological test battery, were more likely to have an abnormal EEG, and to have abnormalities on MRI." | 1.30 | Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. ( Carter, S; Fowler, CJ; Hall-Craggs, MA; Harrison, MJ; Kendall, BE; Lunn, S; Miller, R; Newman, SP; Paley, M; Sweeney, B; Wilkinson, I; Williams, I, 1998) |
| "Four grades of demyelination and three grades of cerebral atrophy were distinguished by magnetic resonance imaging criteria." | 1.28 | 1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders. ( den Hollander, JA; Luyten, PR; Nauta, JJ; Valk, J; van der Grond, J; van der Knaap, MS, 1992) |
| "The effect of implantation of Ehrlich ascites tumor (EAT) cells on creatine distribution was investigated." | 1.28 | Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed beta-guanidinopropionic acid. ( Inoue, N; Ishine, S; Ohira, Y; Yunoki, K, 1991) |
Research
Studies (61)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (13.11) | 18.7374 |
| 1990's | 16 (26.23) | 18.2507 |
| 2000's | 27 (44.26) | 29.6817 |
| 2010's | 10 (16.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Blicher, JU | 1 |
| Eskildsen, SF | 1 |
| Stærmose, TG | 1 |
| Møller, AT | 1 |
| Figlewski, K | 1 |
| Near, J | 1 |
| Bodini, B | 1 |
| Branzoli, F | 1 |
| Poirion, E | 1 |
| García-Lorenzo, D | 1 |
| Didier, M | 1 |
| Maillart, E | 1 |
| Socha, J | 1 |
| Bera, G | 1 |
| Lubetzki, C | 1 |
| Ronen, I | 1 |
| Lehericy, S | 1 |
| Stankoff, B | 1 |
| Crespo-Eguilaz, N | 1 |
| Dominguez, PD | 1 |
| Vaquero, M | 1 |
| Narbona, J | 1 |
| Quadrelli, S | 1 |
| Mountford, C | 1 |
| Ramadan, S | 1 |
| Wang, W | 1 |
| Sun, H | 1 |
| Su, X | 1 |
| Tan, Q | 1 |
| Zhang, S | 1 |
| Xia, C | 1 |
| Li, L | 2 |
| Kemp, GJ | 1 |
| Yue, Q | 1 |
| Gong, Q | 1 |
| Xu, J | 1 |
| Tang, Y | 1 |
| Cecilio Baro, C | 1 |
| Zhang, X | 1 |
| Meng, Z | 1 |
| Li, Y | 1 |
| Rosas, HD | 1 |
| Doros, G | 1 |
| Gevorkian, S | 1 |
| Malarick, K | 1 |
| Reuter, M | 1 |
| Coutu, JP | 1 |
| Triggs, TD | 1 |
| Wilkens, PJ | 1 |
| Matson, W | 1 |
| Salat, DH | 1 |
| Hersch, SM | 2 |
| Auriel, E | 1 |
| Kliper, E | 1 |
| Shenhar-Tsarfaty, S | 1 |
| Molad, J | 1 |
| Berliner, S | 1 |
| Shapira, I | 1 |
| Ben-Bashat, D | 1 |
| Shopin, L | 1 |
| Tene, O | 1 |
| Rosenberg, GA | 1 |
| Bornstein, NM | 1 |
| Ben Assayag, E | 1 |
| Heussinger, N | 1 |
| Saake, M | 1 |
| Mennecke, A | 1 |
| Dörr, HG | 1 |
| Trollmann, R | 1 |
| Kantarci, K | 1 |
| Weigand, SD | 1 |
| Przybelski, SA | 1 |
| Shiung, MM | 1 |
| Whitwell, JL | 1 |
| Negash, S | 1 |
| Knopman, DS | 1 |
| Boeve, BF | 1 |
| O'Brien, PC | 1 |
| Petersen, RC | 1 |
| Jack, CR | 1 |
| García Santos, JM | 1 |
| Fuentes, LJ | 1 |
| Vidal, JB | 1 |
| Carrillo, A | 1 |
| Antequera, M | 1 |
| Campoy, G | 1 |
| Antúnez, C | 1 |
| Torres del Río, S | 1 |
| García-Sevilla, J | 1 |
| Ortega, G | 1 |
| Sarchielli, P | 1 |
| Presciutti, O | 1 |
| Tarducci, R | 1 |
| Gobbi, G | 1 |
| Alberti, A | 1 |
| Pelliccioli, GP | 1 |
| Chiarini, P | 1 |
| Gallai, V | 1 |
| Gambini, A | 1 |
| Falini, A | 1 |
| Moiola, L | 1 |
| Comi, G | 1 |
| Scotti, G | 1 |
| Petroff, OA | 1 |
| Errante, LD | 1 |
| Kim, JH | 1 |
| Spencer, DD | 1 |
| Christodoulou, C | 1 |
| Krupp, LB | 1 |
| Liang, Z | 1 |
| Huang, W | 1 |
| Melville, P | 1 |
| Roque, C | 1 |
| Scherl, WF | 1 |
| Morgan, T | 1 |
| MacAllister, WS | 1 |
| Tudorica, LA | 1 |
| Li, X | 1 |
| Roche, P | 1 |
| Peyster, R | 1 |
| Konaka, K | 1 |
| Ueda, H | 1 |
| Li, JY | 1 |
| Matsumoto, M | 1 |
| Sakoda, S | 1 |
| Yanagihara, T | 2 |
| Tyler, TF | 1 |
| Nicholas, SJ | 1 |
| Hershman, EB | 1 |
| Glace, BW | 1 |
| Mullaney, MJ | 1 |
| McHugh, MP | 1 |
| Lodi, R | 1 |
| Tonon, C | 1 |
| Vignatelli, L | 1 |
| Iotti, S | 1 |
| Montagna, P | 1 |
| Barbiroli, B | 1 |
| Plazzi, G | 1 |
| Briellmann, RS | 1 |
| Wellard, RM | 1 |
| Jackson, GD | 1 |
| Inglese, M | 1 |
| Nusbaum, AO | 1 |
| Pastores, GM | 1 |
| Gianutsos, J | 1 |
| Kolodny, EH | 1 |
| Gonen, O | 1 |
| Kin, T | 1 |
| Hirano, M | 1 |
| Taoka, T | 1 |
| Takamure, M | 1 |
| Furiya, Y | 1 |
| Kichikawa, K | 1 |
| Ueno, S | 1 |
| Huisman, TA | 1 |
| Klein, A | 1 |
| Werner, B | 1 |
| Straube, T | 1 |
| Boltshauser, E | 1 |
| Lantz, G | 1 |
| Seeck, M | 1 |
| Lazeyras, F | 1 |
| Bartsch, AJ | 1 |
| Homola, G | 1 |
| Biller, A | 1 |
| Smith, SM | 1 |
| Weijers, HG | 1 |
| Wiesbeck, GA | 1 |
| Jenkinson, M | 1 |
| De Stefano, N | 2 |
| Solymosi, L | 1 |
| Bendszus, M | 1 |
| Tebartz van Elst, L | 1 |
| Ludaescher, P | 1 |
| Thiel, T | 1 |
| Büchert, M | 1 |
| Hesslinger, B | 1 |
| Bohus, M | 1 |
| Rüsch, N | 1 |
| Hennig, J | 1 |
| Ebert, D | 1 |
| Lieb, K | 1 |
| Roc, AC | 1 |
| Ances, BM | 1 |
| Chawla, S | 1 |
| Korczykowski, M | 1 |
| Wolf, RL | 1 |
| Kolson, DL | 1 |
| Detre, JA | 1 |
| Poptani, H | 1 |
| Schubert, MI | 1 |
| Kalisch, R | 1 |
| Sotiropoulos, I | 1 |
| Catania, C | 1 |
| Sousa, N | 1 |
| Almeida, OF | 1 |
| Auer, DP | 2 |
| Schuff, N | 3 |
| Neylan, TC | 2 |
| Fox-Bosetti, S | 1 |
| Lenoci, M | 1 |
| Samuelson, KW | 1 |
| Studholme, C | 1 |
| Kornak, J | 1 |
| Marmar, CR | 2 |
| Weiner, MW | 3 |
| Güngör, S | 1 |
| Akinci, A | 1 |
| Firat, AK | 1 |
| Tabel, Y | 1 |
| Alkan, A | 1 |
| Azevedo, D | 1 |
| Tatsch, M | 1 |
| Hototian, SR | 1 |
| Bazzarella, MC | 1 |
| Castro, CC | 1 |
| Bottino, CM | 1 |
| Sipilä, I | 4 |
| Rapola, J | 2 |
| Simell, O | 3 |
| Vannas, A | 2 |
| Arjomaa, P | 1 |
| Davie, CA | 1 |
| Wenning, GK | 1 |
| Barker, GJ | 1 |
| Tofts, PS | 1 |
| Kendall, BE | 2 |
| Quinn, N | 1 |
| McDonald, WI | 1 |
| Marsden, CD | 1 |
| Miller, DH | 1 |
| Sibbitt, WL | 1 |
| Haseler, LJ | 1 |
| Griffey, RH | 1 |
| Hart, BL | 1 |
| Sibbitt, RR | 1 |
| Matwiyoff, NA | 1 |
| Nahas, K | 1 |
| le Net, JL | 1 |
| Provost, JP | 1 |
| Tomaszewski, KE | 1 |
| Tedeschi, G | 1 |
| Bertolino, A | 1 |
| Massaquoi, SG | 1 |
| Campbell, G | 1 |
| Patronas, NJ | 1 |
| Bonavita, S | 2 |
| Barnett, AS | 1 |
| Alger, JR | 1 |
| Hallett, M | 1 |
| Ende, GR | 1 |
| Laxer, KD | 1 |
| Knowlton, RC | 1 |
| Matson, GB | 1 |
| Fein, G | 1 |
| Perros, P | 1 |
| Deary, IJ | 1 |
| Sellar, RJ | 1 |
| Best, JJ | 1 |
| Frier, BM | 1 |
| Chung, YL | 1 |
| Smith, EC | 1 |
| Williams, SC | 1 |
| Wassif, WS | 1 |
| Salisbury, JR | 1 |
| Simmons, A | 1 |
| Howlett, DC | 1 |
| Scott, DL | 1 |
| Maeda, H | 1 |
| Furune, S | 1 |
| Nomura, K | 1 |
| Kitou, O | 1 |
| Ando, Y | 1 |
| Negoro, T | 1 |
| Watanabe, K | 1 |
| van der Knaap, MS | 2 |
| Bakker, HD | 1 |
| Valk, J | 2 |
| Harrison, MJ | 1 |
| Newman, SP | 1 |
| Hall-Craggs, MA | 1 |
| Fowler, CJ | 1 |
| Miller, R | 1 |
| Paley, M | 1 |
| Wilkinson, I | 1 |
| Sweeney, B | 1 |
| Lunn, S | 1 |
| Carter, S | 1 |
| Williams, I | 1 |
| Akiguchi, I | 1 |
| Nakano, S | 1 |
| Shiino, A | 1 |
| Kimura, R | 1 |
| Inubushi, T | 1 |
| Handa, J | 1 |
| Nakamura, M | 2 |
| Tanaka, M | 1 |
| Oka, N | 1 |
| Kimura, J | 1 |
| Terakawa, H | 1 |
| Abe, K | 1 |
| Watanabe, Y | 1 |
| Fujita, N | 1 |
| Hirabuki, N | 1 |
| Lundbom, N | 1 |
| Barnett, A | 1 |
| Patronas, N | 1 |
| Rajapakse, J | 1 |
| Di Chiro, G | 1 |
| Li, LM | 1 |
| Cendes, F | 1 |
| Antel, SB | 1 |
| Andermann, F | 1 |
| Serles, W | 1 |
| Dubeau, F | 1 |
| Olivier, A | 1 |
| Arnold, DL | 2 |
| Ferrante, RJ | 1 |
| Andreassen, OA | 1 |
| Jenkins, BG | 1 |
| Dedeoglu, A | 1 |
| Kuemmerle, S | 1 |
| Kubilus, JK | 1 |
| Kaddurah-Daouk, R | 1 |
| Beal, MF | 1 |
| Narayanan, S | 1 |
| Francis, GS | 1 |
| Arnaoutelis, R | 1 |
| Tartaglia, MC | 1 |
| Antel, JP | 1 |
| Matthews, PM | 1 |
| Sijens, PE | 1 |
| Den Heijer, T | 1 |
| De Leeuw, FE | 1 |
| De Groot, JC | 1 |
| Achten, E | 1 |
| Heijboer, RJ | 1 |
| Hofman, A | 1 |
| Breteler, MM | 1 |
| Oudkerk, M | 1 |
| Wilke, M | 1 |
| Grabner, A | 1 |
| Heidenreich, JO | 1 |
| Bronisch, T | 1 |
| Wetter, TC | 1 |
| Hespel, P | 1 |
| Op't Eijnde, B | 1 |
| Van Leemputte, M | 1 |
| Ursø, B | 1 |
| Greenhaff, PL | 1 |
| Labarque, V | 1 |
| Dymarkowski, S | 1 |
| Van Hecke, P | 1 |
| Richter, EA | 1 |
| Lenoci, MA | 1 |
| Du, AT | 1 |
| Weiss, DS | 1 |
| Hofmann, WW | 1 |
| Butte, J | 1 |
| Leon, HA | 1 |
| Wang, Z | 1 |
| Bogdan, AR | 1 |
| Zimmerman, RA | 1 |
| Gusnard, DA | 1 |
| Leigh, JS | 1 |
| Ohene-Frempong, K | 1 |
| van der Grond, J | 1 |
| Luyten, PR | 1 |
| den Hollander, JA | 1 |
| Nauta, JJ | 1 |
| Ohira, Y | 1 |
| Ishine, S | 1 |
| Inoue, N | 1 |
| Yunoki, K | 1 |
| Déli, E | 1 |
| Somlyay, I | 1 |
| Várnagy, L | 1 |
| Vannas-Sulonen, K | 1 |
| Suzuki, H | 1 |
| Wegelius, O | 1 |
| Pasternack, A | 1 |
| Kuhlbäck, B | 1 |
Clinical Trials (4)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans[NCT02729428] | 71 participants (Actual) | Observational | 2016-04-30 | Completed | |||
| Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
| Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)[NCT00712426] | Phase 3 | 553 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.) | ||
| Creatine Safety and Tolerability in Premanifest HD: PRECREST[NCT00592995] | Phase 2 | 64 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Behavioral Frequency Score From Baseline to Month 60
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 1.39 |
| B - Placebo | 1.43 |
Change in Behavioral Frequency x Severity Score From Baseline to Month 60
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 4.29 |
| B - Placebo | 5.06 |
Change in Functional Checklist Score From Baseline to Month 60
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.93 |
| B - Placebo | -8.02 |
Change in Independence Scale Score From Baseline to Month 60
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -26.30 |
| B - Placebo | -24.86 |
Change in Stroop Interference Test - Color Naming From Baseline to Month 60
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -14.21 |
| B - Placebo | -14.51 |
Change in Stroop Interference Test - Interference From Baseline to Month 60
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -7.57 |
| B - Placebo | -8.61 |
Change in Stroop Interference Test - Word Reading From Baseline to Month 60
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -15.25 |
| B - Placebo | -19.13 |
Change in Symbol Digit Modalities Test (SDMT) From Baseline to Month 60
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -10.95 |
| B - Placebo | -11.36 |
Change in Total Functional Capacity (TFC) Score From Baseline to Month 60
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -4.53 |
| B - Placebo | -4.76 |
Change in Total Motor Score From Baseline to Month 60
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 18.06 |
| B - Placebo | 19.18 |
Change in Verbal Fluency Test From Baseline to Month 60
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | -5.07 |
| B - Placebo | -4.47 |
Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | rank (Mean) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 303.3 |
| B - Placebo | 306.7 |
Number Completing Study at Assigned Dosage Level
(NCT00608881)
Timeframe: 5 years
| Intervention | participants completing study on drug (Number) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 98 |
| B - Placebo | 108 |
Time to a Three-Point Decline in TFC Score or Death
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 917 |
| B - Placebo | 911 |
Time to a Two-Point Decline in TFC Score or Death
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
| Intervention | days to event (Median) |
|---|---|
| A - Coenzyme Q10 2400 mg/Day | 553 |
| B - Placebo | 549 |
Reviews
2 reviews available for creatine and Atrophy
| Article | Year |
|---|---|
Systematic review of in-vivo neuro magnetic resonance spectroscopy for the assessment of posttraumatic stress disorder.
Topics: Aspartic Acid; Atrophy; Brain; Creatine; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Hippocampus | 2018 |
Seizure-associated abnormalities in epilepsy: evidence from MR imaging.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Brain Edema; Choline; Creatine; Diffusion Magn | 2005 |
Trials
5 trials available for creatine and Atrophy
| Article | Year |
|---|---|
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.
Topics: Adult; Atrophy; Biomarkers; Brain; Cognition Disorders; Creatine; Cross-Over Studies; Diffusion Magn | 2014 |
Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; Cre | 2003 |
The effect of creatine supplementation on strength recovery after anterior cruciate ligament (ACL) reconstruction: a randomized, placebo-controlled, double-blind trial.
Topics: Administration, Oral; Adult; Anterior Cruciate Ligament; Anterior Cruciate Ligament Injuries; Atroph | 2004 |
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord | 2008 |
Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.
Topics: Adenosine Triphosphate; Administration, Oral; Adult; Atrophy; Body Weight; Creatine; DNA-Binding Pro | 2001 |
Other Studies
54 other studies available for creatine and Atrophy
| Article | Year |
|---|---|
Short echo-time Magnetic Resonance Spectroscopy in ALS, simultaneous quantification of glutamate and GABA at 3 T.
Topics: Aged; Amyotrophic Lateral Sclerosis; Aspartic Acid; Atrophy; Choline; Creatine; Disease Progression; | 2019 |
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
Topics: Adult; Aspartic Acid; Atrophy; Creatine; Diffusion Magnetic Resonance Imaging; Energy Metabolism; Fe | 2018 |
[Developmental amnesia and early brain damage: neuropsychology and neuroimaging].
Topics: Adolescent; Amnesia; Aspartic Acid; Atrophy; Cerebral Palsy; Child; Choline; Creatine; Female; Fetal | 2018 |
Increased right amygdala metabolite concentrations in the absence of atrophy in children and adolescents with PTSD.
Topics: Adolescent; Amygdala; Aspartic Acid; Atrophy; Biomarkers; Child; Choline; Creatine; Cross-Sectional | 2019 |
Left fimbria atrophy is associated with hippocampal metabolism in female major depressive disorder patients.
Topics: Atrophy; Creatine; Depressive Disorder, Major; Female; Hippocampus; Humans; Magnetic Resonance Imagi | 2018 |
Impaired renal function is associated with brain atrophy and poststroke cognitive decline.
Topics: Aged; Atrophy; Brain; Brain Ischemia; Cognitive Dysfunction; Creatine; Diffusion Tensor Imaging; Fem | 2016 |
Variable White Matter Atrophy and Intellectual Development in a Family With X-linked Creatine Transporter Deficiency Despite Genotypic Homogeneity.
Topics: Adolescent; Atrophy; Brain Diseases, Metabolic, Inborn; Child; Creatine; Female; Genotype; Humans; I | 2017 |
Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Biomarkers; Brain; Cerebrovascular Disorders; Cogni | 2009 |
Posterior paralimbic and frontal metabolite impairments in asymptomatic hypertension with different treatment outcomes.
Topics: Aged; Antihypertensive Agents; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Cerebral Hemorrhage; | 2010 |
Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Creatine; Disease Progression; Female; Humans; Magnetic Resonance Spe | 2002 |
Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study.
Topics: Alcohol-Related Disorders; Atrophy; Choline; Corpus Callosum; Creatine; Demyelinating Diseases; Huma | 2003 |
N-acetyl-aspartate, total creatine, and myo-inositol in the epileptogenic human hippocampus.
Topics: Adolescent; Adult; Anterior Temporal Lobectomy; Aspartic Acid; Atrophy; Creatine; Epilepsy, Temporal | 2003 |
N-acetylaspartate to total creatine ratio in the hippocampal CA1 sector after transient cerebral ischemia in gerbils: influence of neuronal elements, reactive gliosis, and tissue atrophy.
Topics: Animals; Aspartic Acid; Astrocytes; Atrophy; Cell Count; Common Variable Immunodeficiency; Creatine; | 2003 |
In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Atrophy; Cataplexy; Creatine; Female; Humans; Hypothalamus; | 2004 |
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Case-Control Studies; Cerebellum; Creatine; Female; Gan | 2005 |
Proton MR spectroscopy of adult-onset dentatorubral-pallidoluysian atrophy.
Topics: Aged; Aspartic Acid; Atrophy; Basal Ganglia Diseases; Case-Control Studies; Choline; Creatine; Denta | 2005 |
Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.
Topics: Aspartic Acid; Atrophy; Brain Diseases; Brain Edema; Cerebellum; Child; Choline; Creatine; Diffusion | 2006 |
Extent of preoperative abnormalities and focus lateralization predict postoperative normalization of contralateral 1H-magnetic resonance spectroscopy metabolite levels in patients with temporal lobe epilepsy.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Electroencephalography; Energ | 2006 |
Manifestations of early brain recovery associated with abstinence from alcoholism.
Topics: Adult; Alcoholism; Aspartic Acid; Atrophy; Attention; Brain; Brain Chemistry; Cerebellum; Choline; C | 2007 |
Evidence of disturbed amygdalar energy metabolism in patients with borderline personality disorder.
Topics: Adult; Amygdala; Anxiety Disorders; Atrophy; Borderline Personality Disorder; Brain Chemistry; Creat | 2007 |
Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy.
Topics: Adult; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Aspartic Acid; Atrophy; Biomark | 2007 |
Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure--an in vivo magnetic resonance spectroscopy and imaging study.
Topics: Animals; Aspartic Acid; Atrophy; Choline; Creatine; Dexamethasone; Energy Metabolism; Glucocorticoid | 2008 |
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning, | 2008 |
Neuroimaging findings in hyperargininemia.
Topics: Arginine; Aspartic Acid; Atrophy; Basal Ganglia Cerebrovascular Disease; Brain Diseases; Cerebellum; | 2008 |
Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina.
Topics: Administration, Oral; Adolescent; Adult; Atrophy; Child; Choroid; Constriction, Pathologic; Creatine | 1981 |
Inhibition of arginine-glycine amidinotransferase by ornithine. A possible mechanism for the muscular and chorioretinal atrophies in gyrate atrophy of the choroid and retina with hyperornithinemia.
Topics: Amidinotransferases; Animals; Arginase; Atrophy; Choroid; Creatine; Glycine; Humans; Kidney; Kinetic | 1980 |
Gyrate atrophy of the choroid and retina with hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine.
Topics: Adolescent; Adult; Amidinotransferases; Arginine; Atrophy; Child; Choroid; Creatine; Female; Glycine | 1980 |
Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Basal Ganglia; Brain Diseases; Choline; Creatine; Diagnosis, Di | 1995 |
Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Choline; Creatine; Energy Metabolism; Female; Huma | 1994 |
An investigation of urinary creatine excretion as a potential marker for testicular damage.
Topics: Animals; Atrophy; Biomarkers; Creatine; Creatinine; Ethylene Glycols; Male; Organ Size; Rats; Rats, | 1993 |
Proton magnetic resonance spectroscopic imaging in patients with cerebellar degeneration.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Humans; Lac | 1996 |
Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Electroencephalography; Epilepsy, Temporal Lobe; F | 1997 |
Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia.
Topics: Adult; Aspartic Acid; Atrophy; Blood Glucose; Brain; Cerebral Cortex; Choline; Cognition; Cohort Stu | 1997 |
In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: a preliminary study.
Topics: Adipose Tissue; Adult; Atrophy; Creatine; Dermatomyositis; Female; Humans; Lipid Metabolism; Magneti | 1997 |
Decrease of N-acetylaspartate after ACTH therapy in patients with infantile spasms.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Anticonvulsants; Aspartic Acid; Atrophy; Brain; C | 1997 |
MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Aspartic Acid; Atrophy; Brain; Brain Diseases, Metabolic; Chil | 1998 |
Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Aspartic Acid; Atrophy; Brain; CD4 | 1998 |
Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Case-Control Studies; Cerebral Cortex; Creatine; Female; | 1999 |
Proton magnetic resonance spectroscopy (1H MRS) in patients with sporadic cerebellar degeneration.
Topics: Adult; Aged; Aspartic Acid; Atrophy; Cerebellar Diseases; Cerebellum; Choline; Creatine; Disease Pro | 1999 |
MR image segmentation and tissue metabolite contrast in 1H spectroscopic imaging of normal and aging brain.
Topics: Adult; Age Factors; Aged; Aging; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine; | 1999 |
Prognostic value of proton magnetic resonance spectroscopic imaging for surgical outcome in patients with intractable temporal lobe epilepsy and bilateral hippocampal atrophy.
Topics: Adolescent; Adult; Aspartic Acid; Atrophy; Brain; Creatine; Dominance, Cerebral; Electroencephalogra | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Aspartic Acid; Atrophy; Brain; Corpus Striatum; Creatine; Cr | 2000 |
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Brain; Chromatography, High Pressure Liquid; Creatine; Disabil | 2001 |
Human brain chemical shift imaging at age 60 to 90: analysis of the causes of the observed sex differences in brain metabolites.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Atrophy; Brain; Brain Chemistry; Choline; Creatine; Female; | 2001 |
Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation.
Topics: Adult; Aspartic Acid; Atrophy; Choline; Creatine; Dominance, Cerebral; Energy Metabolism; Female; Hu | 2001 |
Decreased hippocampal N-acetylaspartate in the absence of atrophy in posttraumatic stress disorder.
Topics: Aspartic Acid; Atrophy; Brain; Case-Control Studies; Creatine; Hippocampus; Humans; Magnetic Resonan | 2001 |
Relationship of intracellular creatine concentration and uptake to muscle mass in vivo.
Topics: Animals; Atrophy; Biological Transport, Active; Creatine; Hypertrophy; Male; Muscle Contraction; Mus | 1978 |
Investigation of stroke in sickle cell disease by 1H nuclear magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Aspartic Acid; Atrophy; Brain; Brain Ischemia; Cerebral Infa | 1992 |
1H and 31P magnetic resonance spectroscopy of the brain in degenerative cerebral disorders.
Topics: Adult; Aspartic Acid; Atrophy; Brain; Brain Diseases; Child; Creatine; Demyelinating Diseases; Human | 1992 |
Reduced growth of Ehrlich ascites tumor cells in creatine depleted mice fed beta-guanidinopropionic acid.
Topics: Administration, Oral; Animals; Atrophy; Carcinoma, Ehrlich Tumor; Cell Division; Creatine; Creatinin | 1991 |
Biochemical study of muscle samples from chicken embryos affected by Wofatox 50 EC.
Topics: Abnormalities, Drug-Induced; Animals; Atrophy; Calcium; Chick Embryo; Cholinesterase Inhibitors; Cre | 1985 |
Gyrate atrophy of the choroid and retina. A five-year follow-up of creatine supplementation.
Topics: Adolescent; Adult; Atrophy; Child; Choroid; Creatine; Female; Follow-Up Studies; Humans; Male; Retin | 1985 |
Effects of vitamin E deficiency and high salt supplementation on changes in kidney and testis of rats.
Topics: Animals; Atrophy; Body Weight; Creatine; Creatinine; Dietary Fats; Fish Oils; Kidney; Linseed Oil; M | 1972 |
Muscular involvement in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspartate Aminotransferases; Atrophy; Biopsy; Creatine; Creatine Kinase; Crea | 1969 |